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A New Name (Pneumocystis 
jiroveci) for Pneumocystis 
from Humans
James R. Stringer,* Charles B. Beard,† Robert F. Miller,‡ and Ann E. Wakefield§1
The disease known as Pneumocystis carinii pneumonia (PCP) is a major cause of illness and death in per-
sons with impaired immune systems. While the genus Pneumocystis has been known to science for nearly
a century, understanding of its members remained rudimentary until DNA analysis showed its extensive
diversity. Pneumocystis organisms from different host species have very different DNA sequences, indicat-
ing multiple species. In recognition of its genetic and functional distinctness, the organism that causes
human PCP is now named Pneumocystis jiroveci Frenkel 1999. Changing the organism’s name does not
preclude the use of the acronym PCP because it can be read “Pneumocystis pneumonia.” DNA sequence
variation exists among samples of P. jiroveci, a feature that allows reexamination of the relationships
between host and pathogen. Instead of lifelong latency, transient colonization may be the rule.
Clinical Importance of Pneumocystis
The disease known as Pneumocystis carinii pneumonia
(PCP) is one of the leading causes of illness and death in per-
sons with impaired immunity. The disease has been described
in immunocompromised patients for many years, including
outbreaks in malnourished young children in orphanages in
Iran in the 1950s (1–6). The AIDS epidemic, however, marked
the beginning of the disease’s impact on a substantial number
of patients. PCP has long been the most common serious
AIDS-defining opportunistic infection in the United States.
The introduction of highly active antiretroviral therapy
(HAART) for the treatment of HIV infection has been accom-
panied by substantial reductions in mortality and the incidence
of opportunistic infections, including PCP (7). Despite these
advances,  Pneumocystis remains a major pathogen in HIV-
infected persons who either are not receiving or are not
responding to HAART and among those who are unaware of
their HIV status. PCP is also of clinical importance in people
immunocompromised for reasons other than HIV, such as
organ transplantation or chemotherapy for malignant diseases
(8). In addition, Pneumocystis infection has been documented
recently in persons who are mildly immunocompromised,
including those with chronic lung disease (9).
Need for a Change in Nomenclature
Pneumocystis organisms were first reported by Chagas in
1909 (10), but he mistook them for a morphologic form of Try-
panosoma cruzi. Within a few years of this first report, further
studies established that the microbe in question was not a trypa-
nosome but a new species altogether, named Pneumocystis cari-
nii (11). 
From the time of its discovery, until late in the 1980s,
Pneumocystis was widely thought to be a protozoan. These
views were based on several criteria: 1) strong similarities in
microbe morphology and host pathology, 2) absence of some
phenotypic features typical of fungi, 3) presence of morpho-
logic features typical of protozoa, 4) ineffectiveness of anti-
fungal drugs, and 5) effectiveness of drugs generally used to
treat protozoan infections. Some investigators pointed out that
Pneumocystis organisms exhibit morphologic similarities to
fungi (2). Nevertheless, the protozoan hypothesis remained
predominant until 1988, when DNA analysis demonstrated
that Pneumocystis is a fungus, albeit an odd one, lacking in
ergosterol and very difficult to grow in culture (12,13). 
Soon after the proper classification of Pneumocystis had
been determined at the kingdom level, additional DNA data
showed that Pneumocystis organisms in different mammals are
quite different. These data led to interim name changes (14),
but it was not until 1999 that the first valid new binomial
appeared. The organism that causes human PCP is now named
Pneumocystis jiroveci Frenkel 1999 (pronounced “yee row vet
zee”), in honor of the Czech parasitologist Otto Jirovec, who is
credited with describing the microbe in humans (15). The pri-
mary purpose of this article is to explain what led to the name
change and why the new name is necessary, useful, and work-
able for all concerned. For a more extensive review of the sys-
tematics and nomenclature of Pneumocystis, see Stringer’s
review of workshops on the subject (16). The DNA sequence
information that led to the renaming of Pneumocytsis
organisms also provided the tools needed to better understand
the relationships between these microbes and the hosts they
inhabit. Thus, the secondary purpose of this article is to sum-
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marize data on these relationships, focusing on current views
on the relationship between P. jiroveci and humans. 
Complexity of the Genus 
One reason that a definitive nomenclature has been slow to
develop is that Pneumocystis organisms have been difficult to
study. Attempts to develop an in vitro culture system have had
limited success. Cultivation of Pneumocystis organisms in
vitro requires a large seed population and supports rather mod-
est increases in organism number for a very limited period of
time (17). An exception to the rule was recently reported (18);
however, this method has not been established in other labora-
tories. The fastidiousness of Pneumocystis organisms greatly
hampered early efforts to understand them. Fortunately,
advances in DNA analysis technology allowed progress in the
absence of a robust culture system. 
Pneumocystis jiroveci as a Distinct Species
Phenotypic differences between P. jiroveci and other spe-
cies of Pneumocystis were noted decades ago (19). More
recent descriptions echo these reports (20). On the basis of
phenotypes, Frenkel first proposed the name Pneumocystis
jiroveci in 1976. The name was not validly published, how-
ever, under the then-prevailing specifications of the Interna-
tional Code of Zoological Nomenclature. Thus, the name did
not gain acceptance at that time. 
The first indication of a molecular difference between P.
jiroveci and Pneumocystis from laboratory animals came from
analyses of protein sizes (21,22). However, the importance of
these differences was difficult to judge because the Pneu-
mocystis was prepared directly from the lung of the host, leav-
ing open the possibility that differences could have been due to
extrinsic factors such as contamination with host proteins,
host-mediated modification of Pneumocystis proteins, or pres-
ence of dead Pneumocystis organisms. 
DNA analysis provided the information needed to clarify
the issue and to establish that the organisms from humans and
other animals are quite different (23). The most powerful
approach has been to use polymerase chain reaction (PCR).
Wakefield developed primers that amplify DNA from all
known species of Pneumocystis (24,25). When these primers
have been used on human-derived samples of Pneumocystis,
the only DNA found has been that of P. jiroveci. Moreover, P.
jiroveci DNA has not been found in lung samples from any
other mammals, including nonhuman primates (26). The PCR
data are supported by the results of sequencing cloned genes.
Several genes or gene fragments have been cloned from
human-derived Pneumocystis (27–30). In all cases, the gene
sequence is very different from its orthologues in Pneumocys-
tis organisms from other host species. Genetic divergence data
also argue that P. jiroveci is a distinct species. The 18S rRNA
sequences from P. jiroveci (i.e., human-derived) and P. carinii
(i.e., rat-derived) differ by 5%. This level of divergence is
comparable with that between Pneumocystis organisms and
Taphrina deformans (a plant fungal pathogen), whose 18S
rRNA sequences differ by approximately 6%. In contrast, spe-
cies in the genus Saccharomyces can differ by as little as 1% at
the 18S rRNA locus. 
The genetic divergence between P. jiroveci and other
Pneumocystis organisms is typical of the genus. When Pneu-
mocystis from different host species are compared by DNA
sequence analysis, they always differ (23,25,31–33). In addi-
tion, experiments with rats, mice, ferrets, and monkeys have
demonstrated host-species specificity (34–36). For example,
when  Pneumocystis organisms were taken from a rat and
transferred to a mouse, proliferation was not evident, and no
disease resulted (34). In contrast, when Pneumocystis organ-
isms from a rat were transferred to another rat, they prolifer-
ated to a very high number and caused severe disease. Transfer
experiments that seem to show lack of specificity have been
reported, but these reports did not show that the proliferating
organisms were the same species of Pneumocystis as those
introduced, leaving open the possibility that endogenous
organisms were responsible for the infection. 
Pneumocystis organisms might be obligate parasites that
have evolved to survive in a particular host species. Co-evolu-
tion of parasite and host might be expected in such a case.
Note, in this regard, that P. jiroveci is most similar to organ-
isms isolated from other primates (37). This finding fits with
the obligate parasite conjecture. However, the host specificity
data also fit with an alternative scenario: there could be many
free-living species of Pneumocystis, one of which is capable of
invading humans, others of which are capable of invading
nonhuman primates, and the like. In this scenario, the similar-
ity between P. jiroveci and the Pneumocystis organisms found
in nonhuman primates would reflect the similarities between
humans and other primates. If P. jiroveci is not an obligate par-
asite, finding it outside the human body should be possible. P.
jiroveci DNA has been detected in samples of airborne fungal
spores (24) and in a sample of pond water (38). However, the
number of P. jiroveci in the environment seems to be very low,
leaving open the possibility that these “free forms” of the
organism may have been deposited by humans. P. jiroveci
could be an obligate parasite, spores of which can survive in
the environment long enough to infect a new host, should one
be encountered. Resolving this question awaits the availability
of a system capable of detecting infectious Pneumocystis
organisms in the air, water, or soil.
Soon after DNA sequence data began to appear, name
changes were suggested (14,39). However, naming new spe-
cies seemed premature to many because of concerns about the
possibility of creating false species by misinterpreting the
importance of a limited amount of DNA sequence data. Con-
sequently, a provisional trinomial nomenclature was adopted.
This system referred to the different kinds of Pneumocystis
organisms as special forms of P. carinii  Under this system, P.
jiroveci was called P. carinii formae specialis hominis ( P.
carinii f. sp. hominis). After these provisional nomenclature
changes were instituted, more DNA sequence data were
obtained, and by 2001, it became clear that the organism caus-Emerging Infectious Diseases  •  Vol. 8, No. 9, September 2002 893
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ing PCP in humans should be recognized as a distinct species.
The name P. jiroveci had already been published in a valid
manner in 1999 (15); however, publication of a name does not
necessarily lead to its use. Therefore, at the 2001 International
Workshops on Opportunistic Protists held in Cincinnati, Ohio,
approximately 50 researchers from around the world, includ-
ing clinicians, epidemiologists, and laboratory scientists, met
to discuss the desirability and appropriateness of retaining the
currently used trinomial nomenclature system, as opposed to
assigning (or using) new species names. The group unani-
mously endorsed a proposal to rename the organisms currently
known as special forms of P. carinii as species in the genus
Pneumocystis and drew up guidelines for the creation of the
new species names (16). Consequently, in keeping with the
International Code of Botanical Nomenclature, it is no longer
correct, either biologically or taxonomically, to refer to the
human Pneumocystis organism as P. carinii. P. carinii now
refers exclusively to the organism formerly known as P. carinii
f. sp. carinii, one of the two Pneumocystis species found only
in rats. 
The consensus achieved at the workshop will help to make
published reports on Pneumocystis more uniform with respect
to nomenclature. Such uniformity will clarify communication
among all who are interested in this genus and the disease
caused by its members. Hopefully, all future reports pertaining
to P. jiroveci will use its new name.
Acronym "PCP" Retained
Given the compelling evidence that the human form of
Pneumocystis is a separate species, the most important objec-
tion to designating it as such has been the problem that this
name change could create in the medical literature, where the
disease caused by P. jiroveci is widely known as PcP, or PCP.
This problem can be avoided by taking the species name out of
the disease name. Under this system, PCP would refer to
Pneumocystis pneumonia. This simple modification in the ver-
nacular accommodates the name change pertaining to the
Pneumocystis species that infects humans. Furthermore,
adopting this change makes the acronym appropriate for
describing the disease in every host species, none of which,
except rats, is infected by P. carinii. 
Multiple Strains of P. Jiroveci 
DNA sequence polymorphisms are often observed in iso-
lates of P. jiroveci, suggesting that numerous strains of this
species exist. Loci that have been favorite targets for sequence
analysis include the mitochondrial large subunit ribosomal
RNA gene, the mitochondrial small subunit rRNA gene, the
internal transcribed spacer regions of the nuclear rRNA gene
(ITS), the arom gene, and the dihydropteroate synthase
(DHPS) gene. The first three of these loci are considered to be
under little if any selective pressure and presumably serve as
indicators of genetic changes that are phenotypically neutral.
The changes in the arom gene may also be considered neutral
because they effect no change in the amino acid sequence of
the enzyme. By contrast, the polymorphisms in the DHPS
gene may be due to selection (see below). Techniques other
than DNA sequencing have been used to detect genotypic vari-
ation. These include the use of type-specific oligonucleotide
probes to detect variation at the ITS regions (40) and detection
of single-strand conformation polymorphism (SSCP) at multi-
ple loci (41). 
Genotyping has produced data from hundreds of P. jiroveci
samples. Most studies have targeted one locus for analysis, but
several multilocus studies have been reported (41–44). The
allelic sequence polymorphism common in P. jiroveci is not
seen in P. carinii (rat-derived Pneumocystis). However, P. car-
inii populations differ with respect to chromosome size, and
several different strains have been identified by analysis of
chromosome sizes (45,46). The possibility of chromosome
size variation in P. jiroveci has not been adequately addressed
because this analysis requires more organisms than are typi-
cally available from patients.
New Perspectives on Infection
Genotyping samples of P. jiroveci provides a method for
exploring epidemiologic issues. For example, one study exam-
ined the possibility that the low incidence of PCP in African
HIV-infected persons might be due to the presence or absence
of certain strains of P. jiroveci. However, samples of P. jiroveci
from Zimbabwe, Brazil, the United States, and the United
Kingdom have exhibited no major differences in genotypes
(47). Another example is a study in which genotyping at four
different genetic loci was used to compare isolates of P.
jiroveci  collected before (1968–1981) and after (1982 to
present) the beginning of the AIDS pandemic (48). Pre- and
postpandemic samples were the same except for a single base
polymorphism (in the mitochondrial large subunit rRNA gene)
found in the pre-pandemic samples only. These data show that
the large increase in incidence of PCP was not accompanied
by a shift in the kinds or frequencies of strains of P. jiroveci. 
Strain analysis has also led to observations that are difficult
to reconcile with the traditional view of the relationship
between P. jiroveci and humans. The traditional theory holds
that clinically important infection results from reactivation of a
latent infection that was acquired during childhood. While
infection of young children appears to be common, latent P.
jiroveci has not been directly observed in healthy adults. In
addition, indirect evidence is difficult to reconcile with life-
long latency.
The latency issue is important for several reasons. Under
the reactivation of latent infection theory, little rationale exists
for instituting measures to minimize the risk of infection during
adulthood because this infection has already occurred. On the
other hand, person-to-person transmission of the disease would
have important public heath implications for medical centers
that treat HIV-infected patients or other immunocompromised
persons (42–44,49–52). Furthermore, transmission fromPERSPECTIVE
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patients who are undergoing treatment for PCP might enhance
the opportunity for drug resistance to arise. By contrast, the
generation of drug resistance would be less of a concern if most
or all infections were due to transmission from an immunocom-
petent person, such as a young child’s mother, or another child
(i.e, someone who is not being treated for PCP). Under these
conditions, drug-resistant strains, if they arose, would not
spread very effectively. 
PCP develops in infants infected with HIV perinatally,
suggesting that P. jiroveci was present in these infants’ envi-
ronments early in their lives (53). Evidence of P. jiroveci has
also been found in some victims of sudden infant death syn-
drome (SIDS) (54). In normal, healthy children, serologic data
have long indicated that infection of young children is com-
mon. Most children develop anti-Pneumocystis antibodies
early in life, and the prevalence of these antibodies appears to
increase with age (48,55). Recently, P. jiroveci has been linked
to clinical illness in normal, healthy infants (51). P. jiroveci
DNA was identified in nasopharyngeal aspirates obtained dur-
ing episodes of mild respiratory infection in 24 (32%) of 74
infants. Seroconversion developed by 20 months of age in 67
(85%) of 79 infants who remained in the study and occurred in
the absence of any symptoms of disease in 14 (18%). These
reports confirm previous ones showing infection of children
(1,3,4). Young children may be a reservoir of infectious P.
jiroveci in the community. 
Although infection of children seems common, little evi-
dence exists for lifelong latency. Using PCR, Wakefield found
no evidence of P. jiroveci in bronchoalveolar lavage fluid from
10 healthy persons (56). Peters replicated this result in post-
mortem lung tissue from 15 immunocompetent adults (56,57).
(The techniques used to detect P. jiroveci have found it in HIV-
negative adults but only those with other health problems
[58].) Studies on recurrent PCP have shown that different P.
jiroveci genotypes are present during different PCP episodes in
patients with repeat episodes of PCP, a result suggestive of
infection proximal to the time of disease (42–44). Recent
infections of adults are also suggested by the high frequency of
mutations that cause changes in the sequence of the DHPS
gene, the enzyme associated with sulfonamide resistance in
other pathogens (59–61). These mutations have not been
detected in patients in whom PCP occurred at a time before the
widespread use of sulfonamides to treat and prevent it (62) but
are common in today's patients, even in those with no known
exposure to sulfonamides (61,63). Mutant DHPS genes have
been found in a variety of P. jiroveci genetic backgrounds, sug-
gesting that selection for DHPS mutations is an ongoing pro-
cess (64). 
An alternative approach to exploring the importance of
latency is employing population genetics and epidemiology to
test the following hypothesis. If lifelong latency is important,
adult patients who reside far from their birthplace should have
the strain of P. jiroveci common in their place of birth, not in
their place of residence. Data pertaining to this hypothesis are
now available (64). The strains infecting adult patients were
more similar to those common in their place of residence than
their place of birth, suggesting that infections had been
recently acquired, rather than carried since early childhood. 
Latent P. jiroveci have not been found in healthy adults,
but proving that they do not exist is practically impossible. A
single organism anywhere in the body could be sufficient to
maintain a latent infection. Therefore, the possibility of
latency remains. However, latent infections may be transitory,
and humans who have eliminated the microbe may be subject
to reinfection. The observations described above seem more
consistent with this “transient colonization” scenario than with
lifelong latency. 
Summary
The microbe that causes PCP in humans is a distinct phylo-
genetic fungal species called Pneumocystis jiroveci. This spe-
cies has been difficult to find in the environment, has not been
found in nonhuman hosts, and is either absent in healthy adults
or present at very low levels. In contrast, P. jiroveci is fairly
common in  humans who have depressed immune function.
The number of P. jiroveci in a person appears to be dependent
on the degree of immune dysfunction, suggesting that the spe-
cies is adapted to exploit this dysfunction, growing to very
high numbers in the severely immunodeficient and to lesser
extents when immune function is less impaired. P. jiroveci
may be eliminated when immune function is optimal. Genetic
variants of the organism are common, providing markers for
epidemiologic studies. Studies using these markers have raised
questions about the role of latency in PCP. Recurrent PCP can
be accompanied by shifts in genotype. Some patients are
infected by genotypes more common in their place of resi-
dence than in their birthplace. Variable loci include the gene
encoding an enzyme targeted by sulfonamides, suggesting
transmission from treated patients to others at risk. While
these observations, combined with the scarcity of P. jiroveci in
healthy adults, do not exclude latency as a cause of PCP, they
suggest that long-term latency is not the only source of this
disease. 
Dr. Stringer is a professor of molecular genetics at the University
of Cincinnati. He has studied the molecular genetics of variation in
the genus Pneumocystis for 15 years.
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